奥拉帕尼诱发阉割耐药前列腺癌患者再生障碍性贫血：病例报告

IF 0.7 Q4 HEMATOLOGY Leukemia Research Reports Pub Date : 2024-01-01 DOI:10.1016/j.lrr.2024.100473

Elrazi A Ali , Monika Jain , Akriti Pokhrel , Unni Mooppan , Jen chin Wang

{"title":"奥拉帕尼诱发阉割耐药前列腺癌患者再生障碍性贫血：病例报告","authors":"Elrazi A Ali , Monika Jain , Akriti Pokhrel , Unni Mooppan , Jen chin Wang","doi":"10.1016/j.lrr.2024.100473","DOIUrl":null,"url":null,"abstract":"<div><p>Olaparib is (ADP‐ribose) polymerase inhibitor (PARPi), which stops the repair of single-stranded DNA breaks. This leads to the death of cancer cells with BRCA1/BRCA2 mutations or homologous recombination deficiency. Since being approved by the FDA in 2023 for treating castrate-resistant prostate cancer (CRPC), there have been some reports of myelodysplastic syndrome (MDS) and acute leukemia linked to PARP inhibitor use for ovarian, breast, pancreatic and breast cancers, there have been no reports of aplastic anemia after receiving PARPi therapy. This case report describes a 75-year-old man with BRCA2-positive metastatic castrate-resistant prostate cancer who developed aplastic anemia after taking olaparib.</p></div>","PeriodicalId":38435,"journal":{"name":"Leukemia Research Reports","volume":"22 ","pages":"Article 100473"},"PeriodicalIF":0.7000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2213048924000633/pdfft?md5=140b9fa865047a5c64dc0e21482883d9&pid=1-s2.0-S2213048924000633-main.pdf","citationCount":"0","resultStr":"{\"title\":\"Olaparib induced aplastic anemia in a patient with castrate resistant prostate cancer: A case report\",\"authors\":\"Elrazi A Ali , Monika Jain , Akriti Pokhrel , Unni Mooppan , Jen chin Wang\",\"doi\":\"10.1016/j.lrr.2024.100473\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>Olaparib is (ADP‐ribose) polymerase inhibitor (PARPi), which stops the repair of single-stranded DNA breaks. This leads to the death of cancer cells with BRCA1/BRCA2 mutations or homologous recombination deficiency. Since being approved by the FDA in 2023 for treating castrate-resistant prostate cancer (CRPC), there have been some reports of myelodysplastic syndrome (MDS) and acute leukemia linked to PARP inhibitor use for ovarian, breast, pancreatic and breast cancers, there have been no reports of aplastic anemia after receiving PARPi therapy. This case report describes a 75-year-old man with BRCA2-positive metastatic castrate-resistant prostate cancer who developed aplastic anemia after taking olaparib.</p></div>\",\"PeriodicalId\":38435,\"journal\":{\"name\":\"Leukemia Research Reports\",\"volume\":\"22 \",\"pages\":\"Article 100473\"},\"PeriodicalIF\":0.7000,\"publicationDate\":\"2024-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.sciencedirect.com/science/article/pii/S2213048924000633/pdfft?md5=140b9fa865047a5c64dc0e21482883d9&pid=1-s2.0-S2213048924000633-main.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Leukemia Research Reports\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2213048924000633\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"HEMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Leukemia Research Reports","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2213048924000633","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"HEMATOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

奥拉帕利是（ADP-核糖）聚合酶抑制剂（PARPi），能阻止单链DNA断裂的修复。这会导致出现 BRCA1/BRCA2 突变或同源重组缺陷的癌细胞死亡。自 2023 年被 FDA 批准用于治疗阉割抗性前列腺癌（CRPC）以来，已有一些骨髓增生异常综合征（MDS）和急性白血病的报告与 PARP 抑制剂用于治疗卵巢癌、乳腺癌、胰腺癌和乳腺癌有关，但尚未有接受 PARPi 治疗后出现再生障碍性贫血的报告。本病例报告描述了一名 75 岁的 BRCA2 阳性转移性耐阉割前列腺癌患者在服用奥拉帕利后出现再生障碍性贫血。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

Olaparib induced aplastic anemia in a patient with castrate resistant prostate cancer: A case report

Olaparib is (ADP‐ribose) polymerase inhibitor (PARPi), which stops the repair of single-stranded DNA breaks. This leads to the death of cancer cells with BRCA1/BRCA2 mutations or homologous recombination deficiency. Since being approved by the FDA in 2023 for treating castrate-resistant prostate cancer (CRPC), there have been some reports of myelodysplastic syndrome (MDS) and acute leukemia linked to PARP inhibitor use for ovarian, breast, pancreatic and breast cancers, there have been no reports of aplastic anemia after receiving PARPi therapy. This case report describes a 75-year-old man with BRCA2-positive metastatic castrate-resistant prostate cancer who developed aplastic anemia after taking olaparib.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊